News about Aphaia: learn more about the latest developments around our company, our research and our products here.

Aphaia Pharma Announces Positive Results from Phase 2 Trial Evaluating its Lead Drug Formulation for Prediabetes Treatment

• Primary endpoint met, showing that APHD-012 improves glucose tolerance in individuals with a pathological oral glucose tolerance test (OGTT) after 6 weeks of administration
• The results provide proof-of-concept for clinical efficacy of Aphaia’s oral glucose formulation, designed to restore endogenous nutrient-sensing pathways in the gastrointestinal tract
• The study confirms that APHD-012 is well tolerated, with no serious adverse events observed
• Additional results from a Phase 2 trial evaluating Aphaia’s formulation in individuals with obesity are expected in H2 2024

Aphaia Pharma Completes Enrollment in Arm 2 of Phase 2 Trial in Individuals with Obesity

• Enrollment has been completed for the last four cohorts evaluating the contribution of circadian effects in weight loss treatment using Aphaia’s formulation
• Topline data anticipated in Q3 and Q4 2024 for Arm 1 and Arm 2 of the trial, respectively

Aphaia Pharma Provides Enrollment and Protocol Update for Phase 2 Trial in Individuals with Obesity

• Enrollment has been completed for the first two cohorts evaluating a once-daily 12g dose of its oral glucose formulation (APHD-012)
• The company is expanding its trial protocol to further explore the contribution of circadian effects in weight loss treatment with four additional cohorts
• Topline data anticipated in Q3 and Q4 2024 for cohorts 1-2 and 3-6, respectively

Aphaia Pharma to Participate in a Panel Discussion at the 10^th LSX World Congress

ZUG, Switzerland, SAN JUAN, Puerto Rico and TORONTO, April 16, 2024 –
Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of obesity and associated metabolic diseases, today announced that Steffen-Sebastian Bolz, M.D., Ph.D., Chief Scientific Officer of Aphaia Pharma, will participate in a panel discussion at the 10^th LSX World Congress, taking place April 29-30, 2024 in London, England.

Aphaia Pharma Announces Dosing of First Patient in its Phase 2 Trial Evaluating its Lead Candidate APH-012 for Prediabetes
Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of obesity and associated metabolic diseases, today announced the first patient has been dosed in a Phase 2 study evaluating the safety and efficacy of its lead candidate, APH-012, to improve glucose tolerance in patients with prediabetes.  

Aphaia Pharma to Participate in the LSX Leaders Inv€$tival Showcase
Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of metabolic diseases, today announced that it will participate in the LSX Leaders Inv€$tival Showcase, to be held November 14, 2022, in London as the pre-day to the Jefferies London Healthcare Conference, November 15-17, 2022.

Aphaia Pharma Announces Enrollment of First Patient in Phase 2 Study of APH-012 for Chronic Weight Management in Individuals with Obesity
Aphaia Pharma, a clinical-stage biopharmaceutical company harnessing precision-targeted drug delivery technology for the treatment and prevention of metabolic diseases, today announced that it has enrolled the first patient as part of a Phase 2 study evaluating the safety and efficacy of its lead drug candidate, APH-012, to induce weight loss in individuals with obesity.